Roche AG

Roche AG
Roche AG  
Discipline: Pharmacology
Pharmacology - Health - Sep 16
Cobas pro integrated solutions improves productivity in the lab and enhances reliability and turnaround times in delivering results to patients By simplifying operations in the lab, Roche is in-turn helping physicians provide evidence-based diagnostic and treatment decisions more cost-effectively and quickly for all patients Roche Diagnostics an
Pharmacology - Health - Sep 13

Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study s

Pharmacology - Health - Sep 12

Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum.

Pharmacology - Health - Sep 10

Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstr

Pharmacology - Health - Sep 4

Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neurofilament light chain levels as a potential biomarker for predicting MS disability progression; new

Pharmacology - Health - Sep 2

Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose oral suspension, a potentially more convenient treatment option for children Children are at high

Pharmacology - Health - Aug 29

This launch represents an important step in Roche's personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000 patients around the world are diagnosed with triple-negative breast cancer, an aggressive disease with limited treatme

Pharmacology - Health - Sep 13

New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency Results will be presented

Pharmacology - Health - Sep 12

Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq (atezolizumab) as a first-line (initial) monotherapy com

Pharmacology - Health - Sep 6

Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC) The combination significantly improved overall survival (OS) an

Health - Pharmacology - Sep 2

BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an important and convenient treatment for both reducing the burden of seasonal flu and limiting the i

Pharmacology - Health - Aug 29

The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer - an aggressive and difficult-to-treat disease Approval based on the Phase III IMpassion130 study, which showed that the combination improved outcomes in people with

Pharmacology - Health - Aug 16

First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek? (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC).

website preview


Medicine and Life Sciences

This site uses cookies and analysis tools to improve the usability of the site. More information. |